Skip to main content

Posts

Showing posts with the label roquefort therapeutics

Lindsay Dudfield, Executive Director and CEO of Jindalee Resources Limited, Executed MOU with POSCO Holdings For Joint Research At McDermitt Lithium Project

JINDALEE RESOURCES LIMITED  (ASX: JRL) (Jindalee, the Company) is an Australian exploration company with Tier 1 lithium deposits in its portfolio in the United States. The Company’s core goals are to discover world-class mineral deposits and generate shareholder wealth. The United States is one of the largest marketplaces for lithium demand, and Jindalee is a leading company committed to help meet future demand. The Company is focussing efforts into developing its McDermitt lithium deposit. Jindalee Resources was listed on the Australian Securities Exchange (ASX) on 11th July 2002 and raised AUD 2.70 million. Now, it is a pure-play United States lithium company. Jindalee’s Projects: In June 2018, the Company acquired McDermitt and Clayton North, two lithium sediment projects in the United States. Both projects are 100% owned by HiTech Minerals Inc., a wholly owned, US-based subsidiary of Jindalee. Several factors attracted the Company’s interest in these projects including: Potenti...
Post a Comment
Read more

Roquefort Therapeutics PLC (LSE: ROQ) And Randox Laboratories Strike Exclusive License Agreement For Medical Diagnostics

  Roquefort Therapeutics PLC (LSE: ROQ, OTCQB: ROQAF), a cancer-focused biotechnology company, has made a significant announcement recently. The Company has signed an   EXCLUSIVE LICENSING AND ROYALTY AGREEMENT   with Randox Laboratories Ltd., a global leader in medical diagnostics. The agreement (“Randox Licence Agreement”) pertains to Roquefort’s Midkine antibody portfolio and is limited to medical diagnostics. As per the Randox Licence Agreement, Roquefort Therapeutics has granted Randox an exclusive worldwide (except Japan) license to use its Midkine antibodies in medical diagnostics. This license agreement is valid for ten years. The two companies will work together on a combined research programme to identify new cancer diagnostics that will be treatable with Roquefort’s Midkine therapeutics. This collaborative effort aims to leverage the strengths of both companies to develop innovative diagnostic solutions for cancer patients. The agreement’s commercial terms rema...
Post a Comment
Read more

Roquefort Therapeutics Reports In-Vivo Safety For Midkine Oncology Antibodies

ROQUEFORT THERAPEUTICS (LSE: ROQ, OTCQB: ROQAF)  (“Roquefort” or the “Company”)  ANNOUNCES  that two of its Midkine (MDK) antibody programs, ROQ-A1 and ROQ-A2, demonstrate  in-vivo  safety in the pre-clinical development programs. The pre-clinical programs were carried out by leading cancer research groups. ROQ-A1 and ROQ-A2 are two patented antibody medicines designed by Roquefort to target metastatic breast cancer and metastatic lung cancer. The experiments demonstrated that ROQ-A1 and ROQ-A2 bind specifically to MDK receptors in cancerous cells in the breast and lung and kill cancer  in vitro . Antibody programs targeting metastatic lung and breast cancer commenced in Q4 2022 at Olivia Newton-John Cancer Research Institute (La Trobe University), Hawkins Laboratory Biochemistry and Genetics (La Trobe University). Both antibodies have demonstrated good safety profiles validated in  in-vivo  models. The targets and milestones were achieved within ...
Post a Comment
Read more

Roquefort Therapeutics and CEO Ajan Reginald: An Inspiring Story

Roquefort Therapeutic’s Portfolio The company’s portfolio includes four best-in-class programs, Midkine antibodies, Midkine RNA therapeutics, STAT-6 siRNA and MK cell therapy, built through the acquisition of Lyramid in 2020 and Oncogeni in 2022: Roquefort has two Midkine programs, developed and run by the acquired Lyramid team. Midkine, a heparin-binding protein, has long been known to be important in embryonic development. While barely detectable in healthy adults, Midkine is highly expressed during oncogenesis. MDK hinders the normal immune response to tumours and promotes metastatic spread to other organs, thereby contributing to various levels of cancer progression and reduced patient survival. Roquefort believes its know-how and patent strategy (the combination of the exclusive license and the efforts to patent in-house R&D) have established the entry barrier in targeting MDK. The patent strategy is focused on both the composition of matter patents and method patents for anti...
Post a Comment
Read more